Last updated on June 2019

Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Brief description of study

This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB- 2640 at one of two doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.

Clinical Study Identifier: NCT03938246

Find a site near you

Start Over